These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19794412)

  • 1. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
    Zhou K; Donnelly L; Burch L; Tavendale R; Doney AS; Leese G; Hattersley AT; McCarthy MI; Morris AD; Lang CC; Palmer CN; Pearson ER
    Clin Pharmacol Ther; 2010 Jan; 87(1):52-6. PubMed ID: 19794412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
    Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.
    Pearson ER; Donnelly LA; Kimber C; Whitley A; Doney AS; McCarthy MI; Hattersley AT; Morris AD; Palmer CN
    Diabetes; 2007 Aug; 56(8):2178-82. PubMed ID: 17519421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.
    Swen JJ; Wessels JA; Krabben A; Assendelft WJ; Guchelaar HJ
    Pharmacogenomics; 2010 Nov; 11(11):1517-23. PubMed ID: 21121772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.
    Visser LE; van Schaik RH; Jan Danser AH; Hofman A; Witteman JC; van Duijn CM; Uitterlinden AG; Pols HA; Stricker BH
    Pharmacogenet Genomics; 2007 Jul; 17(7):473-9. PubMed ID: 17558303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
    Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
    Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Tavridou A; Elens L; Van Schaik RH; Manolopoulos VG
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):60-3. PubMed ID: 24464600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
    Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
    Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing.
    Grant RW; Wexler DJ
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):339-43. PubMed ID: 20222813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
    Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
    Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
    García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
    Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study.
    Tranah GJ; Chan AT; Giovannucci E; Ma J; Fuchs C; Hunter DJ
    Mol Carcinog; 2005 Sep; 44(1):21-30. PubMed ID: 15924351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.
    Guo Y; Zhang Y; Wang Y; Chen X; Si D; Zhong D; Fawcett JP; Zhou H
    Drug Metab Dispos; 2005 Jun; 33(6):749-53. PubMed ID: 15764711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia.
    Holstein A; Hahn M; Patzer O; Seeringer A; Kovacs P; Stingl J
    Eur J Clin Pharmacol; 2011 May; 67(5):471-6. PubMed ID: 21213107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.